Skip to main content
SpringerLink
Log in

Recombinant human erythropoietin in pediatric oncology

  • Chapter
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

  • 923 Accesses

Abstract

Cancer-and treatment-related anemia affects many children diagnosed with a variety of malignancies. The incidence of anemia in children with solid tumors or Hodgkin’s disease at the time of diagnosis has been reported to be 51–74% (Hockenberry et al. 2002). Several pediatric studies report a high incidence of anemia (over 50%) requiring intervention with transfusion in children receiving therapy for Wilms’ tumor, leukemia, and osteosarcoma (Borsi et al. 1995; Green et al. 1998; Nachman et al. 1998). Although baseline hemoglobin values differ by age, gender, and type of cancer, a recent European pediatric survey reported over 80% of children receiving chemotherapy were anemic (Michon 2002). It is clearly a common finding at diagnosis and during the course of treatment for childhood cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A [Suppl 2]: S2–S8

    Article  PubMed  Google Scholar 

  2. Adachi N, et al (1995) Fatal cytomegalovirus myocarditis in a seronegative ALL patient. Acta Paediatr Jpn 37(2): 211–216

    PubMed  CAS  Google Scholar 

  3. Aguilera P (1993) [Blood transfusions in Jehovah’s witnesses]. Rev Med Chil 121(4): 447–451

    PubMed  CAS  Google Scholar 

  4. Albitar S, et al (1995) Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 10 [Suppl 6]: 40–43

    PubMed  Google Scholar 

  5. Almeida-Porada GD, Ascensao JL (1996) Cytomegalovirus as a cause of pancytopenia. Leuk Lymphoma 21(3–4): 217–223

    PubMed  CAS  Google Scholar 

  6. Alpert G, Fleisher GR (1984) Complications of infection with Epstein-Barr virus during childhood: a study of children admitted to the hospital. Pediatr Infect Dis 3(4): 304–307

    Article  PubMed  CAS  Google Scholar 

  7. Beck MN, Beck D (1995) Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 25(1): 17–21

    Article  PubMed  CAS  Google Scholar 

  8. Bennetts G, Bertolone S, Bray G, et al (1995) Erythropoietin reduces volume of red cell transfusions required in some subsets of children with acute lymphocytic leukemia [abstract]. Blood 86 [Suppl 1]: 853a

    Google Scholar 

  9. Blumer J, BS, Adamson PC, et al (2005) Darbopoetin alfo for the treatment of anemia in Pediatric patients with non myeloid malignancies receiving chemotherapy: A phase 1, open-label pharmacokinetic study. In American Society of Pediatric Hematology and Oncology. Washington D.C

    Google Scholar 

  10. Bohlius J, Langensiepen S, Schwarzer G, et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489–498

    Article  PubMed  CAS  Google Scholar 

  11. Bolonaki I, et al (1996) Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 13(2): 111–121

    Article  PubMed  CAS  Google Scholar 

  12. Borsi JD, Ferencz T, Csaki C (1995) Tranfusion requirements of children with cancer and the use of recombinant erythropoietin for the prevention and treatment of cytostatics induced anemia in children. Can J Infect Dis 6 [Suppl C]: 235C (abstract)

    Google Scholar 

  13. Bosanquet N, Tolley K (2003) Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Curr Med Res Opin 19(7): 643–650

    Article  PubMed  Google Scholar 

  14. Buyukpamukcu M, et al (2002) Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol 39(4): 455–458

    Article  PubMed  Google Scholar 

  15. Cappelli C, Ragni G, Clerico A (2002) Recombinant human erythropoietin in pediatric oncology. In: Nowrousian M (ed) Recombinant human erythropoietin (rhEPO) in clinical oncology — scientific and clinical aspects of anemia in Cancer. Springer, Wien New York, pp 313–323

    Google Scholar 

  16. Caro JJ, et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12): 2214–2221

    Article  PubMed  CAS  Google Scholar 

  17. Cazzola M (2000) Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Med Oncol 17 [Suppl 1]: S11–S16

    PubMed  Google Scholar 

  18. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 [3 Suppl 2]: 13–19

    Google Scholar 

  19. Chow E, et al (1999) Effect of hemoglobin on radiotherapy response in children with medulloblastoma: should patients with a low hemoglobin be transfused? Med Pediatr Oncol 32(5): 395–397

    Article  PubMed  CAS  Google Scholar 

  20. Cohen BJ, et al (1997) Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 37(9): 947–952

    Article  PubMed  CAS  Google Scholar 

  21. Corbett TJ, et al (1995) Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant. Bone Marrow Transplant 16(5): 711–713

    PubMed  CAS  Google Scholar 

  22. Cothren C, et al (2002) Blood substitute and erythropoietin therapy in a severely injured Jehovah’s witness. N Engl J Med 346(14): 1097–1098

    Article  PubMed  Google Scholar 

  23. Csaki C, et al (1998) Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 34(3): 364–367

    Article  PubMed  CAS  Google Scholar 

  24. Cunningham RS (2003) Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 26 [6 Suppl]: 38S–42S

    PubMed  Google Scholar 

  25. Demetri GD, et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10): 3412–3425

    PubMed  CAS  Google Scholar 

  26. Demetri GD, et al (2002) Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 3(1): 45–51

    Article  PubMed  CAS  Google Scholar 

  27. Dische S, et al (1983) Carcinoma of the cervix-anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 56(664): 251–255

    Article  PubMed  CAS  Google Scholar 

  28. Dunn A, Carter J, Carter H (2003) Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manage 26(6): 1132–1139

    Article  PubMed  Google Scholar 

  29. Estrin JT, et al (1999) A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 4(4): 318–324

    PubMed  CAS  Google Scholar 

  30. Fanucchi M, et al (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336(6): 404–409

    Article  PubMed  CAS  Google Scholar 

  31. Gabrilove JL (2001) Hematologic malignancies: an opportunity for targeted drug therapy. Oncologist 6 [Suppl 5]: 1–3

    Article  PubMed  Google Scholar 

  32. Gabrilove JL, et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19(11): 2875–2882

    PubMed  CAS  Google Scholar 

  33. Glaspy J (1997) The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 34 [3 Suppl 2]: 20–26

    PubMed  CAS  Google Scholar 

  34. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Huntingt) 13(4): 461–473; discussion 477–478, 483–488

    CAS  Google Scholar 

  35. Grant MJ, Huether SE, Witte MK (2003) Effect of red blood cell transfusion on oxygen consumption in the anemic pediatric patient. Pediatr Crit Care Med 4(4): 459–464

    Article  PubMed  Google Scholar 

  36. Green DM, et al (1998) Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 16(1): 237–245

    PubMed  CAS  Google Scholar 

  37. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91(19): 1616–1634

    Article  PubMed  CAS  Google Scholar 

  38. Hagihara M, et al (2003) Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection. Int J Hematol 78(1): 62–68

    Article  PubMed  Google Scholar 

  39. Hedenus M, et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119(1): 79–86

    Article  PubMed  CAS  Google Scholar 

  40. Henke M, et al (1999) Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 50(2): 185–190

    Article  PubMed  CAS  Google Scholar 

  41. Henke M, et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392): 1255–1260

    Article  PubMed  CAS  Google Scholar 

  42. Henze G, Michon J, Morland B, et al (2002) Phase III randomized study: efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 21: 387a

    Google Scholar 

  43. Hockenberry MJ, et al (2002) Incidence of anemia in children with solid tumors or Hodgkin disease. J Pediatr Hematol Oncol 24(1): 35–37

    Article  PubMed  Google Scholar 

  44. Hockenberry-Eaton M, Hinds PS (2000) Fatigue in children and adolescents with cancer: evolution of a program of study. Semin Oncol Nurs 16(4): 261–272; discussion 272–278

    Article  PubMed  CAS  Google Scholar 

  45. Johnson PW, et al (1991) The use of erythropoietin in a Jehovah’s Witness undergoing major surgery and chemotherapy. Br J Cancer 63(3): 476

    PubMed  CAS  Google Scholar 

  46. Kaptan K, et al (2001) Successful treatment of severe aplastic anemia associated with human parvovirus B19 and Epstein-Barr virus in a healthy subject with allo-BMT. Am J Hematol 67(4): 252–255

    Article  PubMed  CAS  Google Scholar 

  47. Knauss MD, Walton T, Macon EJ (2002) Switching from i.v. to s.c. epoetin in hemodialysis patients. Am J Health Syst Pharm 59(18): 1783–1784

    PubMed  Google Scholar 

  48. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 [Suppl 7A]: 11S–26S

    Article  PubMed  Google Scholar 

  49. Koch WC, et al (1990) Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. J Pediatr 116(3): 355–359

    Article  PubMed  CAS  Google Scholar 

  50. Kotasek D, et al (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39(14): 2026–2034

    Article  PubMed  CAS  Google Scholar 

  51. Kronberger M, et al (2002) Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr Hematol Oncol 19(2): 95–105

    Article  PubMed  CAS  Google Scholar 

  52. Kronberger M, KB, Zoubek A, et al (1995) Prevention of anemia with r-HuEPO in children with Ewing’s or osteogenic sarcoma. Proc Am Soc Clin Oncol 14: 702

    Google Scholar 

  53. Lelieveld P, et al (1984) Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 20(8): 1087–1104

    Article  PubMed  CAS  Google Scholar 

  54. Leon P, et al (1998) Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 30(2): 110–116

    Article  PubMed  CAS  Google Scholar 

  55. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8): 459–460

    Article  PubMed  Google Scholar 

  56. Littlewood TJ, et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19(11): 2865–2874

    PubMed  CAS  Google Scholar 

  57. Littlewood TJ, et al (2003) Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21(4): 169–180

    Article  PubMed  Google Scholar 

  58. MacMillan ML, Freedman MH (1998) Recombinant human erythropoietin in children with cancer. J Pediatr Hematol Oncol 20(3): 187–189

    Article  PubMed  CAS  Google Scholar 

  59. Michon J (2002) Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol 39(4): 448–450

    Article  PubMed  Google Scholar 

  60. Mock V, Olsen M (2003) Current management of fatigue and anemia in patients with cancer. Semin Oncol Nurs 19 [4 Suppl 2]: 36–41

    Article  PubMed  Google Scholar 

  61. Nachman J, et al (1998) Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children’s Cancer Group. J Clin Oncol 16(3): 920–930

    Google Scholar 

  62. Penson RT, Amrein PC (2004) Faith and freedom: leukemia in Jehovah Witness minors. Onkologie 27(2): 126–128

    Article  PubMed  CAS  Google Scholar 

  63. Porter JC, et al (1996) Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 129(5): 656–660

    Article  PubMed  CAS  Google Scholar 

  64. Ragni G, Clerico A, Sordi A, et al (1998) Recombinant human erythropoietin (rHuEpo) in children with cancer: A randomized study [abstract]. Med Pediatr Oncol 31: 274

    Google Scholar 

  65. Rao SP, Miller ST, Cohen BJ (1990) Severe anemia due to B19 parvovirus infection in children with acute leukemia in remission. Am J Pediatr Hematol Oncol 12(2): 194–197

    Article  PubMed  CAS  Google Scholar 

  66. Razzouk BI, Hord JD, Hockenberry M, et al (2006) Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 24: 3583–3589

    Article  PubMed  CAS  Google Scholar 

  67. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303–2320

    Article  PubMed  CAS  Google Scholar 

  68. Rothmann SA, et al (1985) Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning 3(6): 415–423

    Article  PubMed  CAS  Google Scholar 

  69. Sobrero A, et al (2001) Fatigue: a main component of anemia symptomatology. Semin Oncol 28 [2 Suppl 8]: 15–18

    Article  PubMed  CAS  Google Scholar 

  70. Stasi R, et al (2003) Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 98(9): 1786–1801

    Article  PubMed  Google Scholar 

  71. Stuben G, et al (2003) Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 179(9): 620–625

    Article  PubMed  Google Scholar 

  72. Takeshita A, et al (2000) Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group. Br J Haematol 108(1): 55–63

    Article  PubMed  CAS  Google Scholar 

  73. Tenenbaum T, et al (2004) Oncological management of pediatric cancer patients belonging to Jehovah’s Witnesses: a two-institutional experience report. Onkologie 27(2): 131–137

    Article  PubMed  CAS  Google Scholar 

  74. Van-Steenkiste J (2003) Pharmacotherapy of chemotherapy-induced anaemia. Expert Opin Pharmacother 4(12): 2221–2227

    Article  PubMed  CAS  Google Scholar 

  75. Varan A, et al (1999) Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 103(2): E16

    Article  PubMed  CAS  Google Scholar 

  76. Vogelzang NJ, et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 [3 Suppl 2]: 4–12

    PubMed  CAS  Google Scholar 

  77. Wolfe J, et al (2000) Symptoms and suffering at the end of life in children with cancer. N Engl J Med 342(5): 326–333

    Article  PubMed  CAS  Google Scholar 

  78. Yilmaz D, et al (2004) A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 21(1): 1–8

    PubMed  CAS  Google Scholar 

  79. Yount S, Lai JS, Cella D (2002) Methods and progress in assessing the quality of life effects of supportive care with erythropoietin therapy. Curr Opin Hematol 9(3): 234–240

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology and Oncology, Children’s Hospital and Research Center of Oakland, 747 52nd Street, Oakland, CA, 94609, USA

    Caroline Hastings MD (Director of Fellowship)

  2. Pediatric Oncology, Department of Hematology and Oncology, Children’s Hospital and Research Center of Oakland, 747 52nd Street, Oakland, CA, 94609, USA

    Prof. James Feusner MD (Director)

Authors
  1. Caroline Hastings MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. James Feusner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline Hastings MD .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine (Cancer Research), West German Cancer Center, University Hospital of Essen, Essen, Germany

    Mohammad Resa Nowrousian

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag/Wien

About this chapter

Cite this chapter

Hastings, C., Feusner, J. (2008). Recombinant human erythropoietin in pediatric oncology. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-211-69459-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-69459-6_24

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25223-9

  • Online ISBN: 978-3-211-69459-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation